NKTR Stock Analysis: Buy, Sell, or Hold?
NKTR - Nektar Therapeutics
$66.30
-2.36 (-3.44%)
▼
5d:
-10.82%
30d:
-3.89%
90d:
+49.01%
HOLD
MODERATE Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
NKTR is down 5.9% this week, but smart money is accumulating calls. Top strike: $70 2026-05-15 with 2,250 OI. Call ratio: 90% View Scanner →
Strength: 6.9/10
Get Alerted When NKTR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NKTR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: NKTR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: NKTR is currently trading at $66.30, which is considered extended relative to its 30-day fair value range of $69.48 to $74.25.
Technical Outlook: Technically, NKTR is in a strong uptrend. The price is currently testing key support at $67.17. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $128.12 (+86.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NKTR is in a strong uptrend. The price is currently testing key support at $67.17. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $128.12 (+86.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$69.48 -
$74.25
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
45.8%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BULLISH: Trading 86.6% below Wall St target ($128.12)
- CAUTION: 5-day price weakness (-10.8%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$69.48 -
$74.25
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$67.17
Resistance Level
$77.97
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.69
Wall Street Target
$128.13
(+86.6%)
Revenue Growth (YoY)
-25.3%
Profit Margin
-297.1%
Share & Embed Analysis
Last updated: March 30, 2026 12:12 PM ET
Data refreshes hourly during market hours. Next update: 1:12 PM
Data refreshes hourly during market hours. Next update: 1:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NKTR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Jonathan Zalevsky
SELL
180 shares
2026-02-18
Howard W Robin
SELL
423 shares
2026-02-18
Jonathan Zalevsky
SELL
3867 shares
2026-01-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 56 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 63 BUY |
